Immunology: from Cancer to COVID

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Immunology: from Cancer to COVID</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, cancer immunology, and COVID-19."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, cancer immunology, and COVID-19."> <meta property="og:title" content="Immunology: from Cancer to COVID"> <meta name="twitter:description" content="Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, cancer immunology, and COVID-19."> <meta name="twitter:title" content="Immunology: from Cancer to COVID"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/immunology-from-cancer-to-covid"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_338841106-scaled.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_338841106-scaled.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/immunology-from-cancer-to-covid"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Immunotherapy (Non-Oncology) | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Immunology: from Cancer to COVID </h1> <div class="byline"> Edited by Tom Cohen | 18 October 2022 </div> <div class="abstract"> Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, oncology, and COVID-19. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_338841106-scaled.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap">  <h2 id="h-long-covid-autoimmunity-and-cardiac-problems">Long COVID, Autoimmunity, and Cardiac Problems</h2>   <p>David Wraith is a Professor of Immunology and Director of the Institute of Immunology and Immunotherapy at University of Birmingham. Wraith began our panel discussion at <strong>Immuno UK 2022</strong>, titled <strong>Immunology: From Cancer To COVID-19</strong>, and said that at the beginning of the pandemic, he had embarked on a project to develop a sensitive antibody test for the COVID spike protein. “That led us to conduct a lot of studies, first in healthcare workers of different groupings – collecting a lot of samples,” he said.</p>   <blockquote class="wp-block-quote is-style-large"><p>“Frankly, the results were quite frightening”</p></blockquote>   <p>When it was first becoming known that COVID-19 infection could cause long-term post-convalescent syndrome (widely known as long COVID), Wraith and his team decided to run routine clinical autoimmune marker assays on samples collected from patients. “Frankly, the results were quite frightening,” said Wraith.</p>   <p>They looked at the classic, clinically defined autoantibodies in these patients, most of whom had survived the ICU but then developed the long-term sequelae. About 75% of the individuals tested who were convalescent after COVID developed autoantibodies. “What was very interesting was the pattern of autoantibodies,” Wraith added. For example, there was a high instance of epithelial antibodies: “like how you would define <em>bullous pemphigoid</em> – but most of the patients in this group don’t have skin blistering or other symptoms consistent with that.”</p>   <ul><li><a href="https://oxfordglobal.com/immuno/resources/the-challenges-facing-antibody-drug-conjugates-for-immuno-oncology/" target="_blank" rel="noreferrer noopener">The Challenges Facing Antibody-Drug Conjugates for Immuno-Oncology</a></li><li><a href="https://oxfordglobal.com/immuno/resources/immuno-oncology-investigations-the-nkg2d-pathway-diagnostic-biomarker-and-allogenic-car-ts/" target="_blank" rel="noreferrer noopener">Immuno Oncology Investigations: The NKG2D Pathway, Diagnostic Biomarker, and Allogenic CAR Ts</a></li></ul>   <p></p>   <p>Furthermore, Wraith noted that a lot of these patients also had cardiac complications, so his team looked at staining patterns of heart tissue, and staining patterns of skin. “It looked as though the antibodies were staining what the pathologists call the <em>intercellular cement,</em>” explained Wraith.</p>   <p>They also looked for desmosomal proteins in the serum of patients with acute or convalescent COVID and found desmoplakin and desmoglein 2 (not 1 or 3), at high levels in the serum of these patients. “So, we reasoned that if there were proteins being released, then possibly there will be antibodies,” said Wraith.</p>   <p>Given this, Wraith’s team set up a desmoglein 2 screen and validated it. Wraith disclosed that “the patients had remarkably high levels of desmoglein 2 autoantibodies.” Evidence from experimental models shows that antibodies of this type can disrupt desmosomal structures in heart tissue. This effect was corroborated by post-mortem evidence of disrupted intercalated discs the hearts tissue in COVID mortalities.</p>   <p>Wraith said that “we don’t know yet whether there is a direct causal effect. But if there is, and this is a contributor to long-COVID, then there is something we can do about it.” He suggested the possibility of autoantibody removal: suppressing the inflammatory response arising from the impact of the antibodies to reinstate tolerance for these proteins. “So, I think this is a very challenging and potentially interesting area.”</p>   <h2>Using Existing Therapeutics for New Targets</h2>   <p>Also on the panel was Paul Eggleton, Professor & Senior Director of Immunology at Revolo Biotherapeutics, who discussed utilising existing therapeutics for new targets. Eggleton mentioned the fact that evidence suggests that patients with inflammatory bowel disease are at a greater risk of developing Parkinson’s disease. While at UCB, Eggleton and colleagues were interested in the large meta-analyses world-wide, studying if the treatment of IBD patients with an anti-TNF can protect some of these patients going on to develop Parkinson’s disease. “So, repurposing drugs originally used for cancer are sometimes useful to treat autoimmunity. It might also be true for repurposing drugs useful when treating inflammatory disease, that they in turn might be useful to reduce developing some neurodegenerative diseases,” Eggleton noted.</p>   <ul><li><a href="https://oxfordglobal.com/immuno/resources/treating-autoimmune-diseases-past-present-and-future/" target="_blank" rel="noreferrer noopener">Treating Autoimmune Diseases: Past, Present, and Future</a></li><li><a href="https://oxfordglobal.com/immuno/resources/re-educating-the-immune-system-a-brave-new-world-in-immunology/" target="_blank" rel="noreferrer noopener">Re-Educating the Immune System: a ‘Brave New World’ in Immunology</a></li></ul>   <p></p>   <p>Furthermore, Eggleton said that due to COVID, the repurposing of therapies had skyrocketed: “we’ve thrown everything at COVID.” He added that the process for repurposing drugs usually goes through an orderly long and regimented workflow of testing. However, in the COVID pandemic, due to the urgency, many tried and tested immunosuppressive drugs used routinely in humans were fast-tracked for repurposing to treat the inflammatory symptoms of COVID.</p>   <p>“There are numerous ‘named’ autoimmune diseases, but what I often tell medical students is they should probably think of all autoimmune diseases as just one pan-autoimmune disease. Many pro-inflammatory features are similar, but just appear in different tissues. For example, when a patient has one autoimmune disease, they often develop or become susceptible to developing some features of other named autoimmune diseases,” Eggleton noted.</p>   <p>“As biomedical scientists that work to develop drugs to treat autoimmune diseases, we realise that many of the proinflammatory cytokines prevalent in most autoimmune diseases are the same, e.g., TNF, IL-6, IL-17 etc. We also know that most therapies for them focus on inhibiting pro-inflammatory pathways. But this approach itself will not cure a disease, but simply suppress the symptoms.” It was Eggleton’s opinion that it would be far better to attempt to ‘reset’ the pro- and anti-inflammatory balance by inducing immune homeostasis and re-educating the immune system to generate anti-inflammatory cytokines. For example, IL-10, for just as long is required before returning to basal levels.</p>   <ul><li><a href="https://oxfordglobal.com/immuno/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape/" target="_blank" rel="noreferrer noopener">Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape</a></li><li><a href="https://oxfordglobal.com/immuno/resources/abclonals-novel-single-b-cell-based-platform-for-monoclonal-antibody-discovery/" target="_blank" rel="noreferrer noopener">ABclonal’s Novel Single B-Cell Based Platform for Monoclonal Antibody Discovery</a></li></ul>   <p></p>   <p>There are very few single pathways that can be targeted to reset the immune system. The pharmaceutical and biotech industry is turning to cell therapeutics: CAR T cells, CAR T regulatory cells, and the manipulation of dendritic cells. They are doing so, Eggleton explained, “because many diseases have multiple pathways that become dysfunctional—it’s the same common defective pathways in different organs that become impaired, producing different forms of autoimmune disease.” By developing whole cell therapeutics <em>in vitro</em> or <em>in vivo</em>, one may be able to repurpose a cell treatment to work in multiple autoimmune and inflammatory diseases.</p>   <h3>Early-Stage Lung Inflammation: Implications for Chronic Autoimmune and COVID Disease</h3>   <p>Eggleton then recounted a study of patients with bronchiectasis, a rare and severe lung disease of the lung. Bronchiectasis presents when the airways become widened with a thick layer of mucus, which makes patients’ airways a breeding ground for bacteria— “you end up in hospital about four or five times a year.” As Eggleton noted, another complication that sometimes arises from bronchiectasis is rheumatoid arthritis: “So, we thought that there could be a link between lung disease and autoimmune disease – particularly RA.”</p>   <p>“We ran a study at Exeter University Medical School with bronchiectasis patient samples collected from centres in the North-East, South-West, and the Midlands of England. We found that many patients with chronic bronchiectasis had a breakdown of immune tolerance which was not citrulline-specific during the early stages of developing autoimmunity. Furthermore, we found that it became more specific in patients with bronchiectasis in whom rheumatoid arthritis develops. Smoking, which also damages the lungs, is a high-risk factor for going on to develop rheumatoid arthritis. This begs the question ‘is the lung an initiating site of tolerance breakdown prior to developing autoimmune disease many years in the future’?”</p>   <p>Eggleton said that a similar inflammatory process of lung pathology was happening during the pandemic. COVID-19 is another disease of the lung that causes extensive inflammation, much like bronchiectasis, and activates many of the same pro-inflammatory cytokines and cells. Consequently, drugs that were originally approved for use against autoimmune diseases like RA were repurposed for use against COVID-19. An unfortunate supply and demand feature of this was shortages in anti-inflammatory rheumatological medicines emerged during the hight of the COVID pandemic. This was due to the demand of some of these rheumatological drugs being reassigned for treating COVID patients. Eggleton said "it will be of interest to monitor patients with long COVID to see if they develop autoimmune disease with a greater frequency than the non-COVID population in the future.”</p>   <p>The panel discussion then concluded with a question-and-answer session between the audience and panellists.</p>   <p><em>At <a href="https://oxfordglobal.com/tumour-microenvironment/" target="_blank" rel="noreferrer noopener">Tumour Microenvironment: In Person</a>, learn about recent advances in tumour microenvironment research at the basic, translational, and clinical application levels, with exploration of the latest biomarker and spatial technologies to better understand the tumour microenvironment, alongside emerging therapeutic opportunities in immuno-oncology.</em></p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus"> <h4> University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus </h4> <div class="abstract"> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/Clesrovimab%20Shows%20Positive%20Results%20as%20Preventative%20Treatment%20for%20RSV%20in%20Pre-Term%20and%20Full-Term%20Infants.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants"> <h4> Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants </h4> <div class="abstract"> The phase IIb/III met both its primary and secondary endpoints in infants one year old or younger. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/immunology-from-cancer-to-covid"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999448"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999448", "legacyPageId": "hubdb-177607186815-30817717-181072999448", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "f43967a8-d7e4-436e-b7ca-d0775e9af86f", ticks: 1732334656894, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999448", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999448", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Immunology: from Cancer to COVID